Axsome Therapeutics, Inc. Stockholders Equity

• Axsome Therapeutics, Inc. showed an increase of +54.9% in Stockholders Equity from 2024 to 2025.
• This data is from Axsome Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
• XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2016: $41.23 million | Q2 2016: $34.90 million | Q3 2016: $28.18 million | Q1 2017: $29.28 million | Q2 2017: $22.75 million | Q3 2017: $16.84 million | Q1 2018: $12.59 million | Q2 2018: $7.01 million | Q3 2018: $742.8 thousand | Q1 2019: $17.37 million | Q2 2019: $24.28 million | Q3 2019: $6.82 million | Q1 2020: $156.16 million | Q2 2020: $154.24 million | Q3 2020: $135.26 million | Q1 2021: $96.29 million | Q2 2021: $71.44 million | Q3 2021: $42.72 million | Q1 2022: $14.70 million | Q2 2022: $15.20 million | Q3 2022: $157.36 million | Q1 2023: $111.81 million | Q2 2023: $278.80 million | Q3 2023: $269.51 million | Q1 2024: $144.04 million | Q2 2024: $102.85 million | Q3 2024: $92.90 million | Q1 2025: $53.21 million | Q2 2025: $73.08 million | Q3 2025: $73.73 million.
• Over the full 13 years of available data (2013 to 2025), Axsome Therapeutics, Inc.'s Stockholders Equity has grown by 4,454.2%.
• Historical annual values: Fiscal year 2025: $88.30 million | Fiscal year 2024: $57.02 million | Fiscal year 2023: $190.98 million | Fiscal year 2022: $109.56 million | Fiscal year 2021: $15.63 million | Fiscal year 2020: $113.79 million | Fiscal year 2019: $178.72 million | Fiscal year 2018: $937.9 thousand | Fiscal year 2017: $16.72 million | Fiscal year 2016: $21.57 million | Fiscal year 2015: $46.44 million | Fiscal year 2014: -$3.20 million | Fiscal year 2013: -$2.03 million.
• Data sourced from SEC EDGAR public filings as of August 8, 2026.

Last verified: August 8, 2026